Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Change in Inventory (2023 - 2026)

Gyre Therapeutics has reported Change in Inventory over the past 3 years, most recently at $1.2 million for Q4 2025.

Quarterly Change in Inventory rose 923.73% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 69.75% year-over-year, with the annual reading at $3.6 million for FY2025, 69.75% up from the prior year.
Change in Inventory was $1.2 million for Q4 2025 at Gyre Therapeutics, up from -$72000.0 in the prior quarter.
Over five years, Change in Inventory peaked at $1.5 million in Q1 2025 and troughed at -$921000.0 in Q3 2023.
The 3-year median for Change in Inventory is $377000.0 (2024), against an average of $335250.0.
The largest YoY upside for Change in Inventory was 923.73% in 2025 against a maximum downside of 111.32% in 2025.
A 3-year view of Change in Inventory shows it stood at -$184000.0 in 2023, then skyrocketed by 164.13% to $118000.0 in 2024, then soared by 923.73% to $1.2 million in 2025.
Per Business Quant, the three most recent readings for GYRE's Change in Inventory are $1.2 million (Q4 2025), -$72000.0 (Q3 2025), and $954000.0 (Q2 2025).